Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, January 27th.

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Hansa Biopharma reported its Q4 2024 earnings, revealing a larger-than-expected loss and lower-than-forecast revenue. The company posted an EPS of -4.08, significantly missing the forecast of -1.98, ...

Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling. Elevidys ...